5-21-10 Community E-Newsletter/Call

Hi All, the focus of today's call will be to review our Phase 2 web development and request input from the community.

This is an open invitation to get more involved with the world's first ever, unbiased, free license and dynamic medical/health knowledge base. Time: Friday (Today!) 2 - 2:45pm EST Passcode: 634011# If you would like to opt out of these emails, please let me know. Thank you for your continued interest in the OurMed initiative--we couldn't make this happen without your participation and are grateful for you pitching in! Greg Miller, Executive Director at OurMed.Org

(212) 740-1850 Watch our OurMed YouTube Video:http://www.youtube.com/watch?v=zqgYfFxEkLk

OurMed's Technology Update
In today's community call, we'd like you to give your feedback several critical issues related to the site development.

Specifically:

1) Milestone1has been completed. Vincent Navarro's Assessment, Blueliner's Arbab Hassan's view forward and some of the design comps are listed here.

New Facebook technology to affect OurMed!
Keynote address that introduces F8 and the Open Graph project: http://apps.facebook.com/feightlive/

The new features will really re-shape how users interact with other site and how they share information. It will also encourage sites to 6incorporate Facebook's new APIs to draw more traffic.

Following is an article from Arman Rasta, CEO of Blueliner. Blueliner is the vendor developing OurMed Phase 2.

Greg, In the last few weeks, there has been a significant and seismic event in social media. Facebook has launched a whole slew of new features that will certainly change the way we interact with websites and how friends and family in our social networks stay connected with our activities online.

To fully understand the impact these features will have for your business, you have to watch the Facebook presentation that unveiled these features and explains why implementing them on your website could be important to your business. You can watch the presentation and read some thoughts from the Blueliner team by clicking on the link below:

www.bluelinerny.com/blog/2010/04/21/facebook-f8-event-recap-from-san-francisco/

I just wanted to bring this to your attention and let you know that Blueliner can implement these features on your site within days, if you should choose to have them available on your site - which I strongly advise you should! Call or email me if you are interested and I can have one of our project managers on it right away.

Best, Arman Rousta

Building content – What to write about?
Changes or additions can be made easily with our WYSIWYG editor (what you see is what you get), making it much easier than Wikipedia and cutting the volume ramp up rate to the new site significantly faster.

At times posting new material may be difficult to give attributions for so it may be easier to publish previously published work Alternatively, you can choose content from one of the many free content ("copy left") sites such as much of the content on:

1. Medpedia.com

2. NIH's PubMedCentral.gov from the National Library of Medicine

3. Wikipedia.org

4. GanFyd.org (original medical wiki site that claims Medpedia copied them and boasts 2000 site visitors per day)

5. PubMed.org

6. Medline

7. Open.Michigan from the University of Michigan

8. WikiChiro.Org

8. Others?

Posting on OurMed.Org
In addition to the Symbiosis Project, OurMed offers writers of original work to publish a vast range of medical topics. Under the three pillar approach of 1) Being Referenced 2) Being Bold and 3) Being Polite, OurMed strives to be a forum through which multiple health and medical issues are presented and debated.

To write, you must have a free OurMed account. You can write about nearly anything, just keep your comments about new ideas,health and medicine.--It's really important that OurMed gets off the ground using a communities collaborative approach to building it, just as Wikipedia did nine years ago.

We are furthering our editorial policies to include a Style Guide. Feel free to suggest ideas to make this a global "go-to" resource for all healthcare needs fit for any patient or healthcare professional.

Please click on this link to make a small post about whatever's on your mind. You can suggest articles, design or features that you'd like to see on the site. http://ourmed.org/index.php/New_Ideas_for_Site

 Most Active Authors in The Past Month: 


 * Savealife * D Joiner * Gmiller * Arbab * T1 * Vnavarro * PooraviGT * PatrickMullen * Drsjpdc * Elisep

OurMed's MedTool Project
As we develop OurMed's Phase 2 site, we want to announce a competition to inspire our content contributors to come up with the most useful healthcare diagnostic tools from around the world.

Submissions will eventually be open-sourced and written in Joomla so that it will "plug-in" to our new site as well as be available to all around the world in a copy-left offering. To contribute, a contestant need not be tech savy but only be familiar with common health and medical needs. Will it be a simple Body-Mass calculator, Symptom Disease matcher, Diabetic Insulin calculator--the list may go on and one but we want the most popular, best and easiest to use!

24,000 Memphis patients rated their doctors
This article comes to us from Eileen McGinn--Thank you Eileen! I just want to note that rating doctors is something that OurMed does NOT intend to do as it has ethical implications, particularly in countries that have laws against it.

May. 3rd, 2010 by Andrew Van Dam Filed under: Health data, Hot Health Headline

The Healthy Memphis Common Table is an effort to help patients and providers take charge of improving the city’s health. It includes the results of about 24,000 patient ratings of 430 local primary care doctors, all conducted by the nonprofit Consumers’ Checkbook.

Manoj Jain, M.D., M.P.H., (bio) is on the table’s advisory committee and he, as part of its mission to publicize the effort, wrote a three-part series in the The (Memphis) Commercial Appeal on the results and potential of the survey. The first installment is the one with the broadest appeal, as it discusses survey results and consequences.

In the second installment, Jain profiles a highly rated doctor and includes his own musings on what makes a physician great. Jain then wraps up the series with anonymous profiles of two poorly rated doctors and further musings on how their ratings might be improved. Interestingly, Jain’s suggestions almost always focus on non-clinical factors such as office staff quality and communication skills. Bookmark and Share

Consort 2010 Statement: updated guidelines for reporting parallel group randomised trials
 {| width="100%" cellspacing="0" cellpadding="0"
 * Competing interests
 * Authors' contributions
 * Appendix 1: N...
 * Appendix 2: N...
 * Acknowledgements
 * References
 * Acknowledgements
 * References

Research Kenneth F Schulz1, Douglas G Altman2 and David Moher3  for the CONSORT Group

1Family Health International, Research Triangle Park, NC 27709, USA

2Centre for Statistics in Medicine, University of Oxford, Wolfson College, Oxford, UK

3Ottawa Methods Centre, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada The electronic version of this article is the complete one and can be found online at: http://www.trialsjournal.com/&lt;wbr&gt;&lt;/wbr&gt;content/11/1/32 This is an Open Access article distributed under the terms of the Creative C://ommons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract
The CONSORT statement is used worldwide to improve the reporting of randomized controlled trials. Kenneth Schulz and colleagues describe the latest version, CONSORT 2010, which updates the reporting guideline based on new methodological evidence and accumulating experience.

To encourage dissemination of the CONSORT 2010 Statement, this article is freely accessible on bmj.com and will also be published in the Lancet, Obstetrics and Gynecology, PLoS Medicine, Annals of Internal Medicine, Open Medicine, Journal of Clinical Epidemiology, BMC Medicine, and Trials.

Introduction
Randomized controlled trials, when appropriately designed, conducted, and reported, represent the gold standard in evaluating healthcare interventions. However, randomized trials can yield biased results if they lack methodological rigor |[1]. To assess a trial accurately, readers of a published report need complete, clear, and transparent information on its methodology and findings. Unfortunately, attempted assessments frequently fail because authors of many trial reports neglect to provide lucid and complete descriptions of that critical information |||[2-4].

That lack of adequate reporting fueled the development of the original CONSORT (Consolidated Standards of Reporting Trials) statement in 1996 |[5] and its revision five years later |||[6-8]. While those statements improved the reporting quality for some randomized controlled trials, ||[9,10] many trial reports still remain inadequate |[2]. Furthermore, new methodological evidence and additional experience has accumulated since the last revision in 2001. Consequently, we organized a CONSORT Group meeting to update the 2001 statement |||[6-8]. We introduce here the result of that process, CONSORT 2010. |

Intent of CONSORT 2010
The CONSORT 2010 Statement is this paper including the 25 item checklist in the table (Table |1) and the flow diagram (Figure |1). It provides guidance for reporting all randomized controlled trials, but focuses on the most common design type-individually randomized, two group, parallel trials. Other trial designs, such as cluster randomized trials and non-inferiority trials, require varying amounts of additional information. CONSORT extensions for these designs, ||[11,12] and other CONSORT products, can be found through the CONSORT website http://www.consort-statement.&lt;wbr&gt;&lt;/wbr&gt;org website. Along with the CONSORT statement, we have updated the explanation and elaboration article, |[13] which explains the inclusion of each checklist item, provides methodological background, and gives published examples of transparent reporting. Table 1. CONSORT 2010 checklist of information to include when reporting a randomized trial* Flow diagram of the progress through the phases of a parallel randomized trial of two groups (that is, enrollment, intervention allocation, follow-up, and data analysis). Diligent adherence by authors to the checklist items facilitates clarity, completeness, and transparency of reporting. Explicit descriptions, not ambiguity or omission, best serve the interests of all readers. Note that the CONSORT 2010 Statement does not include recommendations for designing, conducting, and analyzing trials. It solely addresses the reporting of what was done and what was found.

Nevertheless, CONSORT does indirectly affect design and conduct. Transparent reporting reveals deficiencies in research if they exist. Thus, investigators who conduct inadequate trials, but who must transparently report, should not be able to pass through the publication process without revelation of their trial's inadequacies. That emerging reality should provide impetus to improved trial design and conduct in the future, a secondary indirect goal of our work. Moreover, CONSORT can help researchers in designing their trial. |

Background to CONSORT
Efforts to improve the reporting of randomized controlled trials accelerated in the mid-1990s, spurred partly by methodological research. Researchers had shown for many years that authors reported such trials poorly, and empirical evidence began to accumulate that some poorly conducted or poorly reported aspects of trials were associated with bias |[14]. Two initiatives aimed at developing reporting guidelines culminated in one of us (DM) and Drummond Rennie organizing the first CONSORT statement in 1996 |[5]. Further methodological research on similar topics reinforced earlier findings |[15] and fed into the revision of 2001 |||[6-8]. Subsequently, the expanding body of methodological research informed the refinement of CONSORT 2010. More than 700 studies comprise the CONSORT database (located on the CONSORT website), which provides the empirical evidence to underpin the CONSORT initiative.

Indeed, CONSORT Group members continually monitor the literature. Information gleaned from these efforts provides an evidence base on which to update the CONSORT statement. We add, drop, or modify items based on that evidence and the recommendations of the CONSORT Group, an international and eclectic group of clinical trialists, statisticians, epidemiologists, and biomedical editors. The CONSORT Executive (KFS, DGA, DM) strives for a balance of established and emerging researchers. The membership of the group is dynamic. As our work expands in response to emerging projects and needed expertise, we invite new members to contribute. As such, CONSORT continually assimilates new ideas and perspectives. That process informs the continually evolving CONSORT statement.

Over time, CONSORT has garnered much support. More than 400 journals, published around the world and in many languages, have explicitly supported the CONSORT statement. Many other healthcare journals support it without our knowledge. Moreover, thousands more have implicitly supported it with the endorsement of the CONSORT statement by the International Committee of Medical Journal Editors http://www.icmje.org website. Other prominent editorial groups, the Council of Science Editors and the World Association of Medical Editors, officially support CONSORT. That support seems warranted: when used by authors and journals, CONSORT seems to improve reporting |[9]. |

Development of CONSORT 2010
Thirty one members of the CONSORT 2010 Group met in Montebello, Canada, in January 2007 to update the 2001 CONSORT statement. In addition to the accumulating evidence relating to existing checklist items, several new issues had come to prominence since 2001. Some participants were given primary responsibility for aggregating and synthesizing the relevant evidence on a particular checklist item of interest. Based on that evidence, the group deliberated the value of each item. As in prior CONSORT versions, we kept only those items deemed absolutely fundamental to reporting a randomized controlled trial. Moreover, an item may be fundamental to a trial but not included, such as approval by an institutional ethical review board, because funding bodies strictly enforce ethical review and medical journals usually address reporting ethical review in their instructions for authors. Other items may seem desirable, such as reporting on whether on-site monitoring was done, but a lack of empirical evidence or any consensus on their value cautions against inclusion at this point. The CONSORT 2010 Statement thus addresses the minimum criteria, although that should not deter authors from including other information if they consider it important.

After the meeting, the CONSORT Executive convened teleconferences and meetings to revise the checklist. After seven major iterations, a revised checklist was distributed to the larger group for feedback. With that feedback, the executive met twice in person to consider all the comments and to produce a penultimate version. That served as the basis for writing the first draft of this paper, which was then distributed to the group for feedback. After consideration of their comments, the executive finalized the statement.

The CONSORT Executive then drafted an updated explanation and elaboration manuscript, with assistance from other members of the larger group. The substance of the 2007 CONSORT meeting provided the material for the update. The updated explanation and elaboration manuscript was distributed to the entire group for additions, deletions, and changes. That final iterative process converged to the CONSORT 2010 Explanation and Elaboration |[13]. |

Health care tries to figure out what works best
By Guy Boulton ♦

Posted: May 2, 2010 |(21) Comments John Maniaci What's the best way to treat prostate cancer? What about an irregular heartbeat? Or back pain? Are new drugs for treating high cholesterol any more effective than older drugs?

No one really knows - including your doctor.

In a health care system that spends $2.5 trillion a year, less than one-tenth of 1% is spent on research to determine what treatment options work best - and, in some cases, whether they work at all.

"We spend billions of dollars on developing new treatments and technologies, but we don't go back through and say, 'OK, how do they work?' " said Murray Ross, director of research at the Kaiser Permanente Institute for Health Policy.

The result is tens of billions of dollars - and maybe much more - spent each year on treatments that are of marginal or questionable value.

In recent years, doctors, economists, health plans, business groups and others have called for increased research on comparative effectiveness - research that compares different treatment options.

That's about to happen.

The American Recovery and Reinvestment Act passed by Congress last year allocated $1.1 billion for the research. And the new health care reform legislation will create a nonprofit institute to fund research on the effectiveness of medical treatments.

The new Patient-Centered Outcomes Research Institute is to receive more than $200 million a year on research starting in 2013 to learn more about which treatments work best for which patients.

"For a physician, the first question is what works," said Maureen Smith, a physician and professor at the University of Wisconsin School of Medicine and Public Health.

The evidence needed to answer that question for specific patients often doesn't exist. As a result, many of the treatment options that confront doctors and patients every day - from which drug to prescribe to complex regimens for chemotherapy - are not based on solid evidence.

Doctors instead must rely on weak or limited studies, expert opinion, anecdotal evidence, their own experience and judgment - and, to some degree, marketing by pharmaceutical and medical device companies.

The Institute of Medicine, the health arm of the National Academy of Sciences, has estimated that fewer than half of treatments given to patients are supported by good evidence.

Others consider that estimate high. Ross estimates that 25% or less of what doctors and other clinicians do isn't based on good evidence.

Examples abound:

When should a patient with narrow arteries be treated with drugs instead of angioplasty, or angioplasty instead of bypass surgery? When is it best to treat atrial fibrillation with drugs, surgery or catheter ablation, a procedure used to scar or destroy tissue that may interfere with the electrical signal to the heart? What's the best way to manage patients with noninvasive breast cancer?

"We have strong evidence for some things, but we have substantially less evidence for most of what we do in medicine," said Paul Keckley, executive director of the Deloitte Center for Health Solutions. Savings goal

Funding research to answer those and other questions could result in better care.

It also could make better use of health care dollars, although that's not guaranteed. Sometimes the most effective treatment costs more. And any savings could be a decade or more away, given the complexity of the studies and the challenges in changing the way doctors practice.

But numerous studies have estimated that as much as one-third of the money spent on medical care doesn't improve patients' health.

One result is the widespread variation in treatments for similar patients, which can be seen in Wisconsin. The Dartmouth Atlas of Health Care found that for every 1,000 people in Medicare in 2005:

• Patients were 107% more likely to have an angioplasty if they lived in Milwaukee instead of La Crosse. They were 39% more likely to have that procedure in Milwaukee than in Marshfield.

• Patients were 120% more likely to have heart bypass surgery if they lived in Wausau instead of Madison. They were 49% more likely to have the surgery if they lived in Milwaukee instead of Madison.

• Patients were 99% more likely to have back surgery if they lived in the Neenah and Oshkosh area instead of Marshfield. They were 88% more likely to have back surgery in Neenah and Oshkosh than Madison.

The variation in common procedures is even larger nationally and, as the Institute of Medicine and others have noted, all of the patients can't be receiving the best care.

Without question, uncertainty is an inherent part of medicine. There are more than 6,000 drugs and 4,000 operations and procedures - not to mention 13,000 medical diagnoses. And each advance raises new questions.

But part of the uncertainty stems from the focus by health care systems on new drugs and procedures. New technology accounts for roughly half of the increase in spending - and new technology in health care almost always costs more.

This focus has resulted in stunning advances in medicine in recent decades. At the same time, doctors want to stay at the forefront of their profession, and they often are quick to adopt new technologies before good evidence exists to show that they work better than existing technologies.

Health care systems can be just as quick to tout new treatments - which almost always pay more - in their marketing campaigns.

The result is that new drugs and technology can outpace the ability of doctors and researchers to determine whether they work better than existing technology. Drug research

Pharmaceutical companies put their research dollars into developing new drugs as opposed to research on how to make the best use of relatively new drugs already on the market, said Ann Nattinger, a physician and professor at the Medical College of Wisconsin.

She doesn't oppose developing new drugs and other treatments. "But we don't have enough evidence on how to use the drugs that we already have," said Nattinger, who is director of the Center for Patient Care and Outcomes Research.

That can be seen in the practice guidelines - recommendations on how to treat specific diseases - developed by medical specialties and others.

For example, a 2006 review of recommendations for preventing and treating breast cancer - Nattinger's research focus - found the overall quality of the available guidelines was "modest."

"There are so many aspects of the treatment that haven't been tested," she said, "so the guidelines end up having to be rather general."

How long should women be treated with hormonal therapy, for example, or what's the best way to manage noninvasive breast cancer?

"All those are still open questions," Nattinger said.

Cardiologists may have the best practice guidelines of any specialty. Yet a recent review of the guidelines developed by the American College of Cardiology and the American Heart Association found that relatively few recommendations were based on high quality evidence.

"It's a shocking deficit," said Matthew Wolff, a cardiologist and professor at the UW medical school. "We have the technology to do it, but we don't spend the money."

One of the quirks of the health care system is that few incentives exist to conduct comparative effectiveness research.

Drug companies in most cases have to show only that a drug works better than nothing, and even then only in carefully controlled conditions for a select group of patients that can differ significantly from those that doctors see day in and day out.

The bar is even lower for medical devices, such as orthopedic implants.

The clinical trials needed to win federal approval for a new drug also are unlikely to detect uncommon side effects because they typically involve relatively few people and often focus on short-term outcomes.

In addition, the people in research trials often are younger and healthier than the patients likely to be given the drug if it wins approval.

"That's probably the biggest distinction between where we have been and where we need to go," said Smith, the UW professor.

An effective treatment for an 80-year-old woman may differ significantly for a 20-year-old woman. "We don't know nearly enough about how to deliver the best care to the entire range of patients," Smith said.

The lack of information isn't limited to new drugs or to the most advanced therapies to treat heart disease or cancer.

The health care system spends $20 billion a year on wound therapy. Which of the competing devices used for negative pressure wound therapy - applying a vacuum on a wound - work best? A review of the available evidence by the federal Agency for Healthcare Research and Quality concluded that this couldn't be determined.

For that matter, whether the devices work any better than standard treatments also isn't known.

Even the most basic care often isn't based on solid evidence. How often a pregnant woman should see her doctor: Four times? Six times? How often should she have an ultrasound? Is an ultrasound even needed for a normal pregnancy?

Doctors don't know, said Sheldon Wasserman, a Milwaukee obstetrician and gynecologist. Setting priorities

That basic question - what's the optimal use of ultrasound during pregnancy - is among 100 priorities for comparative effectiveness research developed by the Institute of Medicine last summer.

The institute was given the task of recommending research priorities for the $1.1 billion allocated under the recovery act. It set up a committee that received more than 2,600 suggestions.

Recommendations range from comparing the effectiveness of complex cancer drugs to the best way to treat attention deficit hyperactivity disorder to treatments for back pain and heart disease.

Funding the research is just the start. The research is complex. Studies often conclude that existing evidence doesn't provide any answers. And even when it does, the answers are rarely clear-cut.

"It is often not that one is better and one is worse," said Alan B. Rosenberg, a physician and vice president who oversees medical policy and technology assessment for WellPoint Inc., the parent of Anthem Blue Cross and Blue Shield of Wisconsin. "It often is the relative benefits and relative harms of the alternatives."

A treatment may work better in some patients and worse in others. Doctors will still have to rely on their judgment and experience.

Another challenge is to persuade doctors and patients to make use of the research. The Institute of Medicine report last year noted that a wide gap exists between the results of the research and the findings' making their way into clinical practice and health policy.

The research also often faces opposition. The proposal to fund more comparative effectiveness research sparked controversy in the debate on health care reform, and that could continue.

Despite the challenges and the controversy, the research has broad support among doctors.

"They are the ones who support this," said UW's Smith, "because they and their patients are the ones who have to make the decisions."

Reporter Guy Boulton conducted research for this series during a fellowship funded by the Kaiser Family Foundation, a nonprofit, nonpartisan health policy research organization with offices in Menlo Park, Calif., and Washington, D.C.

Pioneer Bios
Just like the Wikimedia Foundation that created Wikipedia, OurMed will mostly be driven by volunteers. In addition to the occasional business or technology consultant, the profile for OurMed’s volunteer community will be talented professionals that want to make bring forward the OurMed mission to the end-goal of having a global impact.

To incentivize our founders, we have created the Founding Framer Program. To date, the following folks are eligible and working toward a goal to volunteer more than 100 Communty hours:

Vincente Navarro (OurMed Tech Committee Chair)
212 444 2633 vnavarro@pipeline.com

Research Specialist @ Weill Medical College

Online Database Manager @ Scientists Without Borders

I have done basic science research for over 15 years in the area of prostate cancer. During this time I have had the privilege of working on the development of monoclonal antibodies targeting prostate cancer from concept through clinical trials. This has afforded me a keen insight into development process of therapeutic drugs. In addition, a strong interest in computers has seen me pursue a graduate degree in computer science in addition to my undergraduate in Chemistry. As a result I have designed and developed a clinical trials management system in my laboratory. I am currently the Online Database Manager for Scientists Without Borders. There, I am responsible for the administration of the database and development of the web portal.

Eileen McGinn, MPH (OurMed Content Committee)
MPH/Certificate in Aging, qedeileen@aol.com

Worked in international health and development for 25 years, including several years living in Africa and Asia. Currently PT Research Manager for Nathan Kline Institute, working on the interrelation of poverty and mental health and health equity for persons with disabilities. PT tutor for immigrant high school students at Manhattan Comprehensive Night and Day High School. Volunteer work for many different agencies, including health, disability, immigrant, women's, peace, international. Have written for various websites on health issues. Especially interested in translating technical work into comprehensible language, community-based participatory research and the Capabilities Framework for development and justice.

Geoff Hayden, MD (OurMed Content Committee)
Geoffhayden@gmail.com 615.479.6499 (Cell)

I am a practicing Emergency Physician, splitting time between NYC and South Carolina. I have been in academic practice since 2005 (Residency at Vanderbilt University, Fellowship at University of Pennsylvania), with an emphasis on resident education and emergency ultrasound. My interest in OurMed.org stems from a dissatisfaction regarding the abysmal state of preventive care and a general lack of health care coverage in the U.S. I see OurMed.org as an essential resource to connect patients to health information and health providers.

I imagine my role with OurMed.org in terms of producing content, recruiting other physicians for ongoing contribution, and assisting Greg with the development of a user-friendly, comprehensive clearinghouse of useful health care information.

Geoffrey E. Hayden, MD, FAAEM, FACEP

Adjunct Clinical Professor Vanderbilt University Medical Center Department of Emergency Medicine Nashville, TN Piedmont Medical Center Emergency Department Attending

222 South Herlong Ave Rock Hill, SC 29732

Vanessa Moore (OurMed Recruitment Committee Chair)
MVanellen@ourmed.org 914-665-4534 (home) 914-751-9758 (cell)

Vanessa Moore is a native New Yorker who brings 7 years recruiting experience to the Ourmed recruitment effort. She would like to leverage her experience recruiting volunteers to Ourmed, a forward thinking and progressive approach to disseminating unbiased healthcare information to the public. She has worked in both corporate and nonprofit settings including a consulting engagement for the Department of Education and most recently at the Westchester Independent Living Center, an advocacy group for people with disabilities. She studied Social Sciences at the Lincoln Center campus of Fordham University.

Stephen Press, DC, PhD (OurMed Content Committee Chair)
A practicing Chiropractic physician (33 years). Was chief physician for the "Unified Team" (former USSR) at the XVIth Winter Olympic Games in Albertville, France in 1992. Founded the World Governing body for sports Chiropractic known as "FICS", for Fédération Internationale de Chiropratique du Sport, now headquartered in Lausanne, Switzerland at the Maison Internationale du Sports, and administered in Toronto, at the World Federation of Chropractic offices. I served on the Medical commission of two IOC recognized World Sports Governing bodies; 1st as Chairman for the Fed. Int'l de Roller Sports, and then as Vice-Chairman for FIDE (Chess). Founded the website IAOCO.org, and co-founded WikiChiro.org. Today, I serve as advisor for the International Sports Chiropractic Association, which is the liaison body interacting with the World Olympian's Association. I speak, English, French, Russian and Spanish, play the cello and clarinet, compete in pool, and follow biblical archeology and do artist blacksmithing, making swords and medieval armor as hobbies.

John Volpe (OurMed Tech Committee Content Liaison)
johnvolpe1@yahoo.com 516-221-4692

My background is primarily in accounting, finance and business operations, primarily in the financial services industry. While I'm not a technical professional, I have participated in and managed numerous technical and business projects, primarily involving financial systems. I also worked as a management consultant for a Virginia based company that I did consulting work for the federal and state governments. I am currently retired. In addition to playing tennis and engaging in other physical activities, I volunteer my time and an Account Director with an NYC based organization that provides service grants in the form of a volunteer project team that manages strategy, financial, marketing and development projects for non-profits. My interest in this project is really from the perspective of someone who is a consumer of medical information and is interested in the efficient delivery of medical information to the public.

Richard Knipel, OurMed Content Committee
I have been a volunteer for Wikipedia and other free culture efforts for several years, with a special focus on outreach initiatives to New York area cultural institutions, such as Wikipedia classes at the New York Public Library, museum photography with Wikipedia Loves Art, and urban photography with the TOPP nonprofit with Wikis Take Manhattan. I have served as President of the nonprofit Wikimedia New York City since September 2008. I hope to bring these experiences in helping to build Ourmed into an innovative and rich online healthcare community along the wiki model.

Elise Passikoff, OurMed Tech Committee
Elise Passikoff, OurMed Tech Committee From a background in print and educational publishing, I entered the online world as an editor and technical writer at a start-up software company. There I learned the tools of the trade and gained valuable experience in writing, editing and posting online content. In 2000, I moved to the New York Academy of Sciences [www.nyas.org], where, first as online producer and then as web senior project manager I led the development, implementation, and maintenance of complex online projects, including the ground-breaking website Scientists Without Borders scientistswithoutborders.org].

Diane Joiner, OurMed Content Committee
I have more than 25 years experience in print publishing. I began my career in publishing with Scientific American Magazine; and then transferred to Scientific American Medicine where I was a member of the production department. While at Scientific American Medicine I produced the 2,500 page, two volume, loose-leaf for internal medicine (Scientific American Medicine), as well as the 2,200 page two volume, loose-leaf for surgery (Scientific American Surgery: Practice and Principles). In 2000 I became a member of WebMD’s Professional Publlishing Division. While at WebMD I continued to produce books, pamphlets, and on-line products.

Greg Miller, OurMed Executive Director
at OurMed greg.miller@ourmed.org 212-740-1850

Have 17 years of Corporate Finance and Marketing experience for Fortune 500 companies including nine years abroad (Germany, England and Japan). I've been here in New York since 1996, always passionate about developing new brands, ideas and products. Did Marketing Analysis for ANA, a Japanese Airline, Finance for Cablevision's HD Satellite business and Revlon. Since 2005, I've been inspired by non-profits, created New York's Dance Parade and have worked on OurMed since the Fall of 2008. I'm inspired by the transparent, non-profit approach to the democratization of healthcare. OurMed has a small office at Columbia Medical Center's Audubon Business and Technology Building--Come by and visit us!

3960 Broadway (Entrance on 166th Street) Suite 301 o (212) 740-1850 c (917) 627-7155 greg.miller@ourmed.org

Watch the OurMed Presentation: http://docs.google.com/present/edit?id=0Ad4ohgeyfGzCZGRoNnFuNW1fMzljMmh2OW5jdw&amp;hl=en

Florence Devouard
OurMed Board Member fdevouard@anthere.org

Florence Devouard served as one of the elected representatives to the Wikimedia Foundation Board starting June 2004, and was the Chair of the WMF Board from October 21, 2006 until July 16th, 2008. Florence was born in Versailles (France). She grew up in Grenoble, and has been living since then in several French cities, as well as Antwerpen in Belgium and Tempe in Arizona. She holds two masters, one in Agricultural Sciences (a 5-year degree in agronomical engineering (Diplome d'Ingénieur Grande Ecole) from ENSAIA and the other a postgraduate degree (DEA) in Genetics and Biotechnologies from INPL.She has been working in public research, first in flower plant genetic improvement, and second in microbiology to study the feasability of polluted soil bioremediation. She was employed until 2005 in a French company, to conceive decision-making tools in sustainable agriculture. She is now a consultant in Internet Communication Strategy. She joined the Wikipedia adventure in February 2002 and is known as a contributor under the pseudonym Anthere. Florence is 39, and lives in Clermont Ferrand with her husband Bertrand and her three children, Anne-Gaëlle aged nine, William eleven and Thomas two. On May 16 2008, Florence was made a knight in the French National Order of Merit, proposed by the Ministry of Foreign Affairs as "chair of an international foundation"

Alex Fotopoulos
OurMed Board Secretary alex@broadwaylawoffices.com

Alex Fotopoulos has served on the board since October 2008. He attended Rutgers College in New Brunswick, NJ and then received his Juris Doctor degree from Southwestern University in Los Angeles, California in 1990. He has experience as a litigation attorney and as an entrepreneur. He has held held positions as an attorney and as part of the management team of such high technology companies including AT&amp;T Wireless, T-mobile, Nextel, Metricom, GTE Internetworking as well as small local start-up ventures. He is a licensed Attorney in New York, New Jersey and California.

Stan Kachnowski
OurMed Board Chair swk16@hitlab.org

Stan Kachnowski is one of America’s distinguished scholars in health-care information policy and management having taught e-health and health-care e-business for nearly 20 years. He has authored over 100 scholarly papers and presentations for the world’s leading journals and societies in health-care technology management, informatics and e-governance. In 2003 he was elected as a Fellow in the Royal Society of Medicine in the United Kingdom for his research with the National Health Service in using handhelds to track patient data. In 1996 he was elected to the US-based College of Healthcare Information Management Executives. Stan is currently a visiting professor at the Indian Institute of Technology, New Delhi, India.

Oleta McHenry
OurMed Board Treasurer Newsgirl_fl@hotmail.com

Oleta McHenry was born in Washington D.C. and grew up in Ohio. After graduating high school, she briefly attended Wright State University in Dayton, studying Political Science. She transferred to St. Petersburg College in St. Petersburg, FL and received her A.A. degree in Liberal Arts. Oleta earned her B.S. in Accounting from Florida Metropolitan University in Clearwater, FL in 2006. Oleta worked for the Pulitzer prize winning newspaper, St. Petersburg Times as a circulation manager. After receiving her degree in accounting, she worked briefly in the insurance industry before joining the Wikimedia Foundation as the fulltime accountant of record. While at the Wikimedia Foundation, Oleta helped put in place accounting practices that would help the company in growth and development. She did not follow Wikimedia to San Francisco and now works for a large medical supply company managing the General Ledger for several regions within the United States. Oleta resides in St. Petersburg, FL and works as an accountant.


 * }